Validation of the Tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Chaturvedi, Ashok K ^a   Lazzell, Anna L ^a   Saville, Stephen P ^a   Wormley Jr , Floyd L ^a   Monteagudo, Carlos ^b   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; DOXYCYCLINE; TETRACYCLINE; PROTEIN SYNTHESIS INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FUNGAL CELL; FUNGAL STRAIN; FUNGAL VIRULENCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION SYSTEM; IMMUNE STATUS; INVASIVE CANDIDIASIS; MOUSE; NONHUMAN; PATHOGENESIS; PROMOTER REGION; VALIDATION STUDY; WILD TYPE; ANIMAL; BLOOD; CANDIDIASIS; DISEASE MODEL; DNA RESPONSIVE ELEMENT; DRUG EFFECT; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; KIDNEY; METABOLISM; MICROBIOLOGY; MUTATION; PATHOGENICITY; PHYSIOLOGY; SPLEEN; VIRULENCE;

MURINAE;

ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; CHEMOKINES; CYTOKINES; DISEASE MODELS, ANIMAL; DOXYCYCLINE; GENE EXPRESSION REGULATION, FUNGAL; HOST-PATHOGEN INTERACTIONS; KIDNEY; MICE; MUTATION; PROMOTER REGIONS, GENETIC; PROTEIN SYNTHESIS INHIBITORS; RESPONSE ELEMENTS; SPLEEN; TETRACYCLINE; VIRULENCE;

EID: 79957500651     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020449     Document Type: Article

References (41)

1. Casadevall A, Pirofski L, (2001) Host-pathogen interactions: the attributes of virulence. J Infect Dis 184: 337-344.
2. Casadevall A, Pirofski LA, (1999) Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect Immun 67: 3703-3713.
3. Casadevall A, Pirofski LA, (2002) What is a pathogen? Ann Med 34: 2-4.
4. Biron CA, Casadevall A, (2010) On immunologists and microbiologists: ground zero in the battle for interdisciplinary knowledge. MBio 1: e00260-00210.
5. Falkow S, (2004) Molecular Koch's postulates applied to bacterial pathogenicity--a personal recollection 15 years later. Nat Rev Microbiol 2: 67-72.
6. Baron U, Bujard H, (2000) Tet repressor-based system for regulated gene expression in eukaryotic cells: principles and advances. Methods Enzymol 327: 401-421.
7. Gossen M, Bujard H, (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci U S A 89: 5547-5551.
8. Carroll P, Muttucumaru DG, Parish T, (2005) Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl Environ Microbiol 71: 3077-3084.
9. Lathem WW, Price PA, Miller VL, Goldman WE, (2007) A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 315: 509-513.
10. Meissner M, Agop-Nersesian C, Sullivan WJ Jr, (2007) Molecular tools for analysis of gene function in parasitic microorganisms. Appl Microbiol Biotechnol 75: 963-975.
11. Nakayama H, Izuta M, Nagahashi S, Sihta EY, Sato Y, et al. (1998) A controllable gene-expression system for the pathogenic fungus Candida glabrata. Microbiology 144: 2407-2415.
12. Nakayama H, Mio T, Nagahashi S, Kokado M, Arisawa M, et al. (2000) Tetracycline-regulatable system to tightly control gene expression in the pathogenic fungus Candida albicans. Infect Immun 68: 6712-6719.
13. Vogt K, Bhabhra R, Rhodes JC, Askew DS, (2005) Doxycycline-regulated gene expression in the opportunistic fungal pathogen Aspergillus fumigatus. BMC Microbiol 5: 1.
14. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, et al. (1996) A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A 93: 14014-14019.
15. Dunston CR, Griffiths HR, Lambert PA, Staddon S, Vernallis AB, (2011) Proteomic analysis of the anti-inflammatory action of minocycline. Proteomics 11: 42-51.
16. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, et al. (1995) The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 36: 418-424.
17. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, et al. (1999) A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci U S A 96: 13496-13500.
18. D'Agostino P, Arcoleo F, Barbera C, Di Bella G, La Rosa M, et al. (1998) Tetracycline inhibits the nitric oxide synthase activity induced by endotoxin in cultured murine macrophages. Eur J Pharmacol 346: 283-290.
19. Fonzi WA, Irwin MY, (1993) Isogenic strain construction and gene mapping in Candida albicans. Genetics 134: 717-728.
20. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL, (2003) Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous frms of Candida albicans during infection. Eukaryot Cell 2: 1053-1060.
21. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, et al. (2009) Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
22. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172-1177.
23. Pfaller MA, Diekema DJ, (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
24. Viudes A, Peman J, Canton E, Ubeda P, Lopez-Ribot JL, et al. (2002) Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 21: 767-774.
25. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, et al. (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317.
26. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, et al. (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939-949.
27. Netea MG, Brown GD, Kullberg BJ, Gow NA, (2008) An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 6: 67-78.
28. Odds FC, Gow NA, Brown AJ, (2001) Fungal virulence studies come of age. Genome Biol 2: 1009.1001-1004.
29. Romani L, (2004) Immunity to fungal infections. Nat Rev Immunol 4: 1-23.
30. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL, (2008) Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun 76: 97-102.
31. MacCallum DM, Odds FC, (2005) Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice. Mycoses 48: 151-161.
32. Spellberg B, Ibrahim AS, Edwards JE Jr, Filler SG, (2005) Mice with disseminated candidiasis die of progressive sepsis. J Infect Dis 192: 336-343.
33. Spellberg B, Johnston D, Phan QT, Edwards JE Jr, French SW, et al. (2003) Parenchymal organ, and not splenic, immunity correlates with host survival during disseminated candidiasis. Infect Immun 71: 5756-5764.
34. Becker JM, Kauffman SJ, Hauser M, Huang L, Lin M, et al. (2010) Pathway analysis of Candida albicans survival and virulence determinants in a murine infection model. Proc Natl Acad Sci U S A 107: 22044-22049.
35. Roemer T, Jiang B, Davison J, Ketela T, Veillette K, et al. (2003) Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol 50: 167-181.
36. Agwuh KN, MacGowan A, (2006) Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256-265.
37. Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, Lopez-Ribot JL, et al. (2009) Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci USA 106: 599-604.
38. Eger K, Hermes M, Uhlemann K, Rodewald S, Ortwein J, et al. (2004) 4-Epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models. Biochem Biophys Res Commun 323: 979-986.
39. Park YN, Morschhauser J, (2005) Tetracycline-inducible gene expression and gene deletion in Candida albicans. Eukaryot Cell 4: 1328-1342.
40. Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F, (2009) In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev 61: 527-541.
41. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA, (2002) Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 13: 121-128.